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Introduction 
One third of all breast cancers occur in women over 70yrs. Surgery with adjuvant anti-
oestrogens and primary endocrine therapy have equivalent overall survival rates, however 
local control rates are superior in surgically treated patients. For women at intermediate risk 
of surgery there are a complex series of trade-offs to be made in deciding between the two 
treatments.  The decision about whether or not to have chemotherapy is also complex as the 
risks are higher and the benefits smaller among this age group.  
Currently, there is little evidence to support clinicians/patients with these treatment 
decisions.  This trial aims to evaluate the effectiveness of decision support interventions 
(DESIs) to assist in the treatment decision-making of older women with early breast cancer. 
The DESIs include two patient decision aids (primary endocrine therapy versus surgery plus 
adjuvant endocrine therapy and chemotherapy versus no chemotherapy) and a clinical 
treatment outcomes algorithm for clinicians. 
 
Methods and analysis 
 
This multi-centre, parallel group, pragmatic cluster randomised controlled trial (RCT) has 
recruited 46 UK breast sites cluster randomised to either usual practice for women (≤70 
years) with breast cancer (control) or, usual practice plus the use of the DESIs (intervention). 
The primary outcome being QoL. Secondary outcomes include decision quality/regret, 
anxiety, illness perceptions and coping. A process evaluation is being undertaken  to assess 
the implementation, usefulness and acceptability of the DESIs and examine the 




The trial opened in January 2016 and closes in December 2017. We aim to recruit 1500 





This trial will determine the effectiveness of the implementation of two DESIs on health care 
outcomes and will provide high quality evidence to support treatment decision making 
among this group of women.    
